; p& T- Y2 N$ U7 R1 W/ I( `Zhiqiang An, "Therapeutic Monoclonal Antibodies: From Bench to Clinic" / l& w) E0 T8 m/ n" R/ GWiley | 2009 | ISBN: 0470117915 | 905 pages | PDF | 11,4 MB 2 \* G1 k3 ~+ W2 w+ [' f
4 R4 S0 a+ ]( v9 w, F. x70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies. / h* h/ Q8 V7 c u" jFirst book to address the discovery and development of antibody therapeutics in their entirety.# I2 H: C$ {: S* v' p2 f4 ~
Most chapters contain experimental data to illustrate the principles described in them.2 O3 m& S/ E2 g; K+ D8 `
Authors provide detailed methodologies that readers can take away with them and use in their own laboratories % e7 @& `- l5 y# s& @9 j- w( n, g 2010-7-12 18:23:52 上传下载附件 (32.22 KB) 5 O% N! ?2 X. w0 R6 G5 h# ~4 e( Q; F0 n( p
THERAPEUTIC MONOCLONAL ANTIBODIES -141 @# z% _* F6 D* E$ e
CONTENTS -12; B4 F3 K* N; Y; i) K0 h
FOREWORD -8 / C9 R1 U+ { a& Q# f# t" |$ X PREFACE -63 r8 d8 x# S8 o5 n X E! M% M
CONTRIBUTORS -4 4 _* G3 Z- o! a8 ]: M PART I ANTIBODY BASICS 1 1 ]0 l" i- e; u! _3 h! u) b 1. Therapeutic Monoclonal Antibodies: Past, Present, and Future 3 * g4 [3 N5 |+ {) d5 R6 n+ Z 2. Antibody Molecular Structure 51 8 n P3 ^, I5 F( G4 X 3. Glycosylation of Therapeutic IgGs 677 @( I5 h9 U" I8 j
4. Antibody Databases and Tools: The IMGT(? Experience 91 - q* E! F* b9 F6 n6 n' H. [ PART II ANTIBODY SOURCES 115& Z$ ]5 `8 z* H( j9 B& n
5. Human Antibodies from Transgenic Mice 1173 F! _* Q/ ^: ?* d9 E D3 ] `' ]: g
6. Rabbit Hybridoma 151 0 P, m( |( E7 @6 w" d: s 7. Human Antibody Repertoire Libraries 169- h8 l7 I' x- c) S6 [
PART III IN VITRO DISPLAY TECHNOLOGY 189+ g/ E" C/ ?8 w3 f" r
8. Antibody Phage Display 191" K6 J9 D* P3 w8 x T3 F: }$ r
9. Yeast Surface Display 213: v; a8 Z- W0 U( R# I2 i$ d0 w7 s
10. Ribosomal Display 239 # O$ g: p# T# T" f% }% N) j 11. Bacterial Display of Antibodies 255 v% p- B: B# c7 Y
12. Antibody Selection from Immunoglobulin Libraries Expressed in Mammalian Cells 2831 g6 F& F! M) B1 v
PART IV ANTIBODY ENGINEERING 309 4 w0 [, d% l; y8 H) I 13. Antibody Engineering: Humanization, Affinity Maturation, and Selection Techniques 3114 e& |2 s1 v4 |3 R7 {5 ?6 h
14. Modulation of Serum Protein Homeostasis and Transcytosis by the Neonatal Fc Receptor 335 9 y1 T2 H: F* ?$ }1 E8 K' i 15. Engineering the Antibody Fc Region for Optimal Effector Function 349 ( T6 q5 Y, Z0 [: s( i' D1 t PART V PHYSIOLOGY AND IN VIVO BIOLOGY 371 ' C! h, L9 A* i* B 16. Antibody-Complement Interaction 373- w3 v, z3 J# T* I
17. Bacteria Immunoglobulin-Binding Proteins: Biology and Practical Applications 385 z" V; k3 G# f2 b9 O! l, z 18. Immunogenicity Screening Using in Silico Methods: Correlation between T-Cell Epitope Content and Clinical Immunogenicity of Monoclonal Antibodies 417 9 \5 C( u) J- h 19. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics 439! I$ r7 w: x0 O5 A: p
20. Biodistribution and Imaging 4610 V3 P+ }# ]: ?4 b* @7 b, X
21. Antibodies and the Blood-Brain Barrier 483 $ e% k3 ^3 A6 K PART VI ANTIBODY CHARACTERIZATION 503 - m2 R; [% @4 H% t 22. Determination of Equilibrium Dissociation Constants 5051 u8 G1 b$ g3 V- ^
23. Molecular and Functional Characterization of Monoclonal Antibodies 5253 a9 }7 Y" X" \ L
24. Characterization of Heterogeneity in Monoclonal Antibody Products 541 1 @- ^0 |$ S7 z& n4 l# @ PART VII ANTIBODY EXPRESSION 555& g3 D9 V* ~0 B: n
25. Antibody Expression in Mammalian Cells 557 2 ]0 ~0 B% ^8 Y+ S7 b) A 26. Production of Antibodies in Pichia pastoris 573 ^7 _. _: r" _- K7 w* Y, ^( A 27. Production of Antibody Fab' Fragments in E. coli 589 0 }/ t6 S( \/ Z/ _) n4 _* ` 28. Production of Human Therapeutic Monoclonal Antibodies in Chicken Eggs 623* E4 U: y9 }4 C6 [1 I
29. Production of Antibodies in Plants 651 0 j& S, C S- a' v- O2 T PART VIII THERAPEUTIC ANTIBODIES 6738 r7 F- N( R; c( S: I5 ]
30. The Formulation and Delivery of Monoclonal Antibodies 675! ]; d2 m5 Q+ \" R) A& [
31. Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates 711 7 v! R6 [3 G D* L- P 32. Follow-On Protein Products: What, Where, When, How? 7638 p% g& k4 x2 b% ?# K
33. Monomeric Fc Fusion Molecules 779 Y; g% V0 k# a0 T, P( q% f 34. Radioimmunotherapy: Current Status and Future Directions 797 " X1 m: n6 R2 I; _7 e 35. Antibody-Drug Conjugate Therapy 821 4 \. B- ]2 V8 L# f ABBREVIATIONS 8579 p5 M- N7 K. n! _& \' F
INDEX 8651 ?6 |) V2 Q: C0 m9 G# v9 A& ^
